patent cliff

$ABBV and $BMY deliver above-average dividend yields and growth, standing out as rare healthcare sector exceptions for patient income investors navigating patent cliffs through innovation.

Bristol Myers Squibb's attractive 4.4% dividend yield faces headwinds from major patent expirations on blockbuster drugs Eliquis and Opdivo.

Healthcare sector faces pullback amid Middle East tensions, but dividend-paying stocks and funds offer yields of 6-14.1% with varying risk profiles.

Catalyst Pharmaceuticals trades at 20-33% discount to peers with 7.5% FCF yield; 2026 Hetero litigation is binary catalyst determining if shares reach $28-32 or collapse to $16-20.

BMY and MDT offer attractive dividend yields and growth potential, with BMY at 4% yield and MDT boasting 48 years of consecutive increases.

Patent strength, not clinical efficacy, will drive GLP-1 market leadership as clinical outcomes converge. Companies with robust IP portfolios may capture disproportionate market share despite comparable results.

Regeneron's Dupixent dominance and deep pipeline across weight management, oncology, and rare diseases position the company for sustained growth through the mid-2030s.

Novartis maintains growth despite patent challenges, backed by a strong product portfolio of 15 billion-dollar brands and nearly 30 years of consecutive dividend increases.

Pfizer's 6.3% dividend yield depends on GLP-1 drug success and managing upcoming patent cliffs as it competes against rivals Novo Nordisk and Eli Lilly in obesity treatments.